Operator
Good day, and thank you for standing by. Welcome to the Idorsia Full Year 2025 Financial Results Conference Call and Webcast. [Operator Instructions] Please be advised that today’s conference is being recorded.
I would now like to hand the conference over to our first speaker today, Srishti Gupta, CEO. Please go ahead.
Srishti Gupta
CEO & Executive Director
Thank you, Nadia. Good afternoon and good morning, everyone, and welcome to our webcast to discuss the financial results of 2025. My name is Srishti Gupta, I’m the CEO of Idorsia, and I’ll start the call today with an overview of the operational progress we made in 2025 and the exciting plans we have for 2026. I’ll then hand it over to Arno Groenewoud, our CFO, to walk you through the company’s financial position. We’ll then take your questions.
Next slide, please. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties and other factors. These may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.
Next slide, please. We entered 2025 facing significant financial pressure, but we leave the year stronger and more focused. 2025 was a year of stabilization and preparation. We reinforced our balance sheet, delivered disciplined commercial execution and positioned our pipeline for decisive milestones ahead. Most importantly, we continued advancing medicines that address meaningful unmet needs for patients.
Our Idorsia-led QUVIVIQ sales for 2025
Read the full article here
